India's Biocon Issues One-For-One Bonus Shares, Says Acquisitions, New Drug Development To Drive Earnings
This article was originally published in PharmAsia News
Executive Summary
BANGALORE, India - India's largest biotechnology drug firm Biocon said clinical trials for diabetes, psorasis, arthritis and cancer drugs are progressing and it plans to launch a new cardio-diabetes division to focus on brand building for its statin Statix (atorvastatin)
You may also be interested in...
India’s Biocon Buys 70 Percent Stake In German Drug Firm AxiCorp GmbH
BANGALORE, India - India's Biocon Ltd. said it paid €30 million ($43.5 million) to buy a 70 percent stake in German drug firm AxiCorp GmbH to expand marketing and distribution of products such as injectable insulin, generics, biosimilars and biologics in Europe
Biocon Partners With Biotech Startup In Latest India-U.S. Deal
NEW DELHI - Biocon, India's largest biotechnology company, said it would list its Syngene research service unit next financial year and make a "strategic" investment in U.S. firm IATRICa to co-develop a new class of immunoconjugates that provides targeted immunotherapy for cancers and infectious diseases
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Abraxis BioScience and Biocon have signed a licensing agreement that gives the Los Angeles firm the right to develop a biosimilar of granulocyte-colony stimulating factor in North America and the European Union, the companies announced July 19